Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
MRL Ventures Fund
AddedFeb 13, 2024
UpdatedJun 28, 2026
MRL Ventures Fund

MRL Ventures Fund

Operating

MRLV, a Cambridge-based VC fund, invests globally in innovative firms developing transformative medicines.

Location
Cambridge, MA, US
Founded
2014
Firm
Compare
Portfolio
Fundraising
Employees

Investments

Therini Bio
Therini Bio

Total Raised

$65.3M

Rounds

4

Series A$36MApril 2023
Seed$17MMay 2021
Carisma Therapeutics
Carisma Therapeutics
Public

Total Raised

$151.9M

Rounds

8

Series C$30MSeptember 2022
Series B$12MMarch 2021
Series B$47MJanuary 2021
Series A$53MJune 2018
Photys Therapeutics
Photys Therapeutics

Total Raised

$75M

Rounds

1

Series A$75MSeptember 2022
Aktis Oncology
Aktis Oncology

Total Raised

$156M

Rounds

2

Series A$84MAugust 2022
LifeMine Therapeutics
LifeMine Therapeutics

Total Raised

$295M

Rounds

3

Series C$175MMarch 2022
Series B$50MJanuary 2021
Series A$70MSeptember 2017
Ambagon Therapeutics
Ambagon Therapeutics

Total Raised

$148M

Rounds

3

Series A$85MJanuary 2022
Mozart Therapeutics
Mozart Therapeutics

Total Raised

$80M

Rounds

2

Series A$55MOctober 2021
PAQ Therapeutics
PAQ Therapeutics

Total Raised

$30M

Rounds

1

Series A$30MJuly 2021
Entrada Therapeutics
Entrada Therapeutics
Public

Total Raised

$201.6M

Rounds

5

Series B$116MMarch 2021
Series A$59MDecember 2018
Tallac Therapeutics
Tallac Therapeutics

Total Raised

$88.2M

Rounds

3

Series A$62MDecember 2020
HotSpot Therapeutics
HotSpot Therapeutics

Total Raised

$210M

Rounds

4

Series B$65MMay 2020
Kymera Therapeutics
Kymera Therapeutics
Public

Total Raised

$879M

Rounds

8

Series B$65MNovember 2018
Alector
Alector
Public

Total Raised

$269.5M

Rounds

7

Series E$133MJuly 2018
Series D$29.5MJanuary 2016
Series C$32MSeptember 2015
Spero Therapeutics
Spero Therapeutics
Public

Total Raised

$443.6M

Rounds

16

Series C$51.7MMarch 2017
Series B$30MFebruary 2016